A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19

NCT04555213 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
41
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Noxopharm Limited